This trial is active, not recruiting.

Condition breast cancer
Sponsor Centre Oscar Lambret
Start date August 2005
End date December 2014
Trial size 490 participants
Trial identifier NCT01183832, ORACLES


This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
In this group, anastrazole is concomitant to the radiotherapy
In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)

Primary Outcomes

radiation side effects
time frame: 5 years after the end of radiotherapy

Eligibility Criteria

Female participants of any age.

Inclusion Criteria: - Post-menopausal woman without superior age limit - No metastatic breast cancer, stade I-II, estrogen receptor positive or progesterone receptor positive, treated by conservative surgery or total mastectomy and requiring additive treatment by radiotherapy and hormonotherapy - The patients including in another clinical trial can be include in this observatory

Additional Information

Official title Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects
Principal investigator Yazid BELKACEMI, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in August 2014.
Information provided to ClinicalTrials.gov by Centre Oscar Lambret.